The "GATA6 Gene Pancreatic Agenesis and Congenital Heart Defects Genetic Test" is a specialized diagnostic tool offered by DNA Labs UAE, designed to detect mutations in the GATA6 gene. Mutations in this gene are known to cause pancreatic agenesis, a rare condition where the pancreas fails to develop properly, leading to diabetes and related issues from birth. Additionally, these mutations can result in various congenital heart defects, which are structural problems with the heart present from birth. The test is crucial for early diagnosis and management of these conditions, providing essential information for personalized treatment plans and family planning. The cost of the test is 4400 AED, making it a valuable investment for families with a history of these genetic conditions, offering them peace of mind and the ability to make informed health decisions.
The TRPM4 Gene Progressive Familial Heart Block Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to identify mutations in the TRPM4 gene, which are associated with progressive familial heart block (PFHB). PFHB is a rare genetic disorder characterized by the progressive impairment of electrical signals in the heart, leading to abnormal heart rhythms and potentially serious heart conditions.
The TRPM4 gene plays a crucial role in the normal electrical functioning of the heart, and mutations in this gene can disrupt this process, leading to the development of heart block. Early detection of these mutations through genetic testing can provide valuable information for managing and treating affected individuals, potentially preventing severe complications.
The test is priced at 4400 AED and involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory for the presence of mutations in the TRPM4 gene. Results from this test can help guide clinical decisions, including the need for further diagnostic evaluations, interventions, or monitoring strategies tailored to the individual's genetic risk profile. It's an important tool for families with a history of PFHB, offering insights that can inform both current treatment plans and future family planning decisions.
The SFTPA1 gene plays a crucial role in lung health, encoding a protein essential for maintaining the surface tension within the alveoli and for protecting the lungs from inhaled microbes and environmental toxins. Mutations in the SFTPA1 gene have been associated with an increased risk of developing idiopathic pulmonary fibrosis (IPF), a chronic, progressive lung disease characterized by the thickening and scarring (fibrosis) of lung tissue, which significantly impairs breathing and oxygen transfer.
Recognizing the genetic component in the susceptibility to IPF, DNA Labs UAE offers a specialized genetic test aimed at identifying mutations in the SFTPA1 gene. This test is an invaluable tool for individuals with a family history of pulmonary fibrosis or for those presenting symptoms of the disease, providing them with crucial information regarding their risk and aiding in the early detection and management of the condition.
The test is priced at 4400 AED, reflecting the comprehensive analysis and personalized interpretation of results it entails. Conducted in state-of-the-art facilities by a team of expert geneticists and clinicians, the SFTPA1 gene test is a significant step forward in the personalized approach to the diagnosis and management of idiopathic pulmonary fibrosis, offering patients and their families the information necessary to navigate this challenging condition.
The CRHR1 Gene Pulmonary Newborn Hypertension Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the CRHR1 gene that are associated with pulmonary hypertension in newborns. Pulmonary hypertension is a serious condition characterized by high blood pressure in the blood vessels that supply the lungs, which can lead to significant health issues. The CRHR1 gene plays a crucial role in the body's response to stress and the regulation of blood pressure, making mutations in this gene a potential risk factor for developing pulmonary hypertension.
This genetic test is critical for early detection and management of the condition, allowing healthcare providers to implement appropriate interventions and treatments to improve outcomes for affected newborns. The process involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in the laboratory to detect any genetic abnormalities in the CRHR1 gene.
The cost of the CRHR1 Gene Pulmonary Newborn Hypertension Genetic Test at DNA Labs UAE is 4400 AED. This investment in early diagnosis can be invaluable for families, providing essential information for the management of the condition and potentially improving the quality of life and health outcomes for affected infants.
The EIF2AK4 gene pulmonary venoocclusive disease type 2 genetic test is a specialized diagnostic procedure aimed at identifying mutations in the EIF2AK4 gene, which are known to cause pulmonary venoocclusive disease (PVOD) type 2. This condition is a rare form of pulmonary hypertension characterized by the obstruction of small veins in the lungs, leading to significant breathing difficulties and heart failure if left untreated. The genetic test is crucial for early diagnosis and management of the condition, providing vital information for personalized treatment plans.
Performed at DNA Labs UAE, the test involves collecting a DNA sample, typically through a blood draw, and analyzing it for specific genetic alterations in the EIF2AK4 gene. The cost of the test is set at 4400 AED, reflecting the specialized nature of the analysis and the expertise required to accurately interpret the results. By identifying individuals with these genetic mutations, healthcare providers can offer targeted interventions, potentially improving outcomes and quality of life for those affected by PVOD type 2.
The KCNQ1 Gene Jervell and Lange-Nielsen Syndrome Type 1 Genetic Test is a specialized diagnostic procedure offered at DNA Labs UAE, designed to identify mutations in the KCNQ1 gene. This gene is crucial for the proper function of heart cells, and mutations can lead to Jervell and Lange-Nielsen syndrome type 1, a rare condition characterized by profound deafness from birth and a long QT interval on an electrocardiogram, which increases the risk of arrhythmias and sudden death. The test is particularly important for individuals with a family history of the syndrome or related symptoms, enabling early diagnosis and management of the condition. Priced at 4400 AED, this genetic test is a critical tool in the proactive care and treatment planning for affected individuals, providing them with a clearer understanding of their genetic health related to this specific cardiac and auditory syndrome.
The KCNE1 Gene Jervell and Lange-Nielsen Syndrome Type 2 Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to identify mutations in the KCNE1 gene, which are associated with Jervell and Lange-Nielsen Syndrome Type 2 (JLNS2). JLNS2 is a rare inherited condition characterized by profound bilateral sensorineural hearing loss and long QT syndrome, which can lead to arrhythmias and sudden cardiac death. The test is crucial for individuals with a family history of JLNS2 or those exhibiting symptoms related to the condition, as it can confirm the diagnosis and help in managing the syndrome effectively. The cost of the test is 4400 AED, reflecting the sophisticated technology and expertise required to accurately detect the genetic variations linked to this syndrome. Through early detection provided by the KCNE1 Gene Test, affected individuals can receive timely intervention and counseling, significantly improving their quality of life and reducing the risk of life-threatening cardiac events.
The DTNA Gene Left Ventricular Noncompaction 1 with or without Congenital Heart Defects Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE, aimed at identifying mutations in the DTNA gene that are associated with Left Ventricular Noncompaction 1 (LVNC1). LVNC1 is a rare cardiomyopathy characterized by the failure of the heart's muscular layer to develop normally, leading to a spongy and noncompacted appearance of the left ventricle. This condition can occur with or without additional congenital heart defects.
The test is designed to provide critical insights for individuals suspected of having this condition, as well as for families seeking to understand their genetic risk. Early detection through genetic testing can be pivotal in managing and treating the condition effectively, potentially improving the quality of life and outcomes for affected individuals.
Priced at 4400 AED, the test is conducted in the state-of-the-art facilities of DNA Labs UAE, ensuring high accuracy and reliability of results. By opting for this test, patients and healthcare providers can make informed decisions regarding surveillance, management strategies, and familial genetic counseling, contributing to personalized and precise medical care.
The MIB1 Gene Left Ventricular Noncompaction 7 Genetic Test is a specialized diagnostic examination available at DNA Labs UAE, designed to detect mutations in the MIB1 gene, which are associated with Left Ventricular Noncompaction 7 (LVNC7). LVNC7 is a rare form of cardiomyopathy characterized by the abnormal development of the left ventricle, leading to a spongy and noncompacted myocardium that can significantly impair heart function. This condition is genetic, and identifying mutations in the MIB1 gene can provide crucial information for diagnosis, management, and familial genetic counseling. The test is priced at 4400 AED and is conducted using advanced genetic sequencing technologies to ensure accurate and reliable results. Given the complexity and rarity of LVNC7, this test represents a vital tool for healthcare providers in the diagnosis and treatment planning for affected individuals.
The TLR5 gene plays a crucial role in the immune system's response to bacterial infections, including Legionnaires' disease, a severe form of pneumonia caused by the Legionella bacteria. Variations in the TLR5 gene can influence an individual's susceptibility to Legionnaires' disease, making some people more prone to developing severe symptoms if they encounter the Legionella bacteria.
DNA Labs UAE offers a specialized genetic test aimed at identifying variations in the TLR5 gene that may increase an individual's susceptibility to Legionnaires' disease. This test is particularly valuable for individuals with a family history of the disease or those in occupations with a high risk of exposure to Legionella bacteria, such as plumbing, HVAC maintenance, or working in environments where water systems may harbor the bacteria.
The test costs 4400 AED and involves a simple process where a small sample of DNA is collected, typically through a saliva swab or a blood sample. The sample is then analyzed in the laboratory to detect any genetic variations in the TLR5 gene that may indicate a higher risk of developing Legionnaires' disease. Results from this test can provide crucial information for individuals to take preventive measures or for medical professionals to develop a personalized treatment plan in the event of an infection.
By offering this test, DNA Labs UAE provides an essential tool for enhancing personal health management and contributing to the prevention of Legionnaires' disease through genetic insights.
